Trial · NCT01955837
Results by group120
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 120
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival（OS） | TAS-102（Trifluridine/Tipiracil） | 7.8 | 95% Confidence Interval 7.1 to 8.8 | Months | |
| Overall Survival（OS） | Placebo | 7.1 | 95% Confidence Interval 5.9 to 8.2 | Months | |
| Progression-free Survival (PFS) | TAS-102（Trifluridine/Tipiracil） | 2.0 | 95% Confidence Interval 1.9 to 2.8 | Months | |
| Progression-free Survival (PFS) | Placebo | 1.8 | 95% Confidence Interval 1.7 to 1.8 | Months | |
| Time to Treatment Failure (TTF) | TAS-102（Trifluridine/Tipiracil） | 1.9 | 95% Confidence Interval 1.9 to 2.2 | months | |
| Time to Treatment Failure (TTF) | Placebo | 1.8 | 95% Confidence Interval 1.7 to 1.8 | months | |
| Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria) | TAS-102（Trifluridine/Tipiracil） | 1.1 | 95% Confidence Interval 0.2 to 3.3 | percentage of participants | |
| Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria) | Placebo | 0.0 | 95% Confidence Interval 0.0 to 2.8 | percentage of participants | |
| Disease Control Rate (DCR; CR, PR, or Stable Disease) | TAS-102（Trifluridine/Tipiracil） | 44.1 | 95% Confidence Interval 37.9 to 50.3 | percentage of participants | |
| Disease Control Rate (DCR; CR, PR, or Stable Disease) | Placebo | 14.6 | 95% Confidence Interval 9.0 to 21.9 | percentage of participants | |
| Duration of Response | TAS-102（Trifluridine/Tipiracil） | 6.6 | 95% Confidence Interval 3.9 to 9.2 | Months | |
| Duration of Response | Placebo | 0 | 95% Confidence Interval 0 to 0 | Months | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | TAS-102（Trifluridine/Tipiracil） | No AEs | 2 | Participants | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | Placebo | No AEs | 15 | Participants | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | TAS-102（Trifluridine/Tipiracil） | One or more AEs | 269 | Participants | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | Placebo | One or more AEs | 120 | Participants | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | TAS-102（Trifluridine/Tipiracil） | One or more TEAEs | 269 | Participants | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | Placebo | One or more TEAEs | 118 | Participants | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | TAS-102（Trifluridine/Tipiracil） | TEAE severity by CTCAE grade:Grade1 | 23 | Participants | |
| Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments（Adverse Events） | Placebo | TEAE severity by CTCAE grade:Grade1 | 32 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01955837/results